The estimated Net Worth of Dianne C. Whitfield is at least $1.26 Million dollars as of 15 March 2024. Ms Whitfield owns over 11,711 units of Tarsus Pharmaceuticals stock worth over $1,224,141 and over the last 4 years she sold TARS stock worth over $40,501.
Ms has made over 7 trades of the Tarsus Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 11,711 units of TARS stock worth $372,410 on 15 March 2024.
The largest trade she's ever made was exercising 23,920 units of Tarsus Pharmaceuticals stock on 29 November 2023 worth over $760,656. On average, Ms trades about 4,832 units every 43 days since 2021. As of 15 March 2024 she still owns at least 38,495 units of Tarsus Pharmaceuticals stock.
You can see the complete history of Ms Whitfield stock trades at the bottom of the page.
Dianne C. Whitfield is the Chief HR Officer at Tarsus Pharmaceuticals.
Ms Whitfield is 44, she's been the Chief HR Officer of Tarsus Pharmaceuticals since . There are 3 older and 3 younger executives at Tarsus Pharmaceuticals. The oldest executive at Tarsus Pharmaceuticals, Inc. is Michael Holdbrook, 68, who is the VP of Clinical Affairs.
Dianne's mailing address filed with the SEC is C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE, CA, 92618.
Over the last 4 years, insiders at Tarsus Pharmaceuticals have traded over $38,362,333 worth of Tarsus Pharmaceuticals stock and bought 1,047,656 units worth $16,525,269 . The most active insiders traders include Investments, Lpwong Roderic..., Capital Ix, Llc Vivo Capita..., and William J Phd Link. On average, Tarsus Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $729,047. The most recent stock trade was executed by William J Phd Link on 12 August 2024, trading 35,000 units of TARS stock currently worth $912,800.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Tarsus Pharmaceuticals executives and other stock owners filed with the SEC include: